Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | PARP inhibitors for ovarian cancer

Kathleen Moore • 30 Sep 2019
ESMO 2019
Gynecological Cancer Ovarian Cancer
PAOLA-1 SOLO-1

Kathleen Moore, MD, Stephenson Cancer Center, Oklahoma City, OK, talks about the treatment landscape of ovarian cancer with the emergence of PARP inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Kathleen Moore

5:03
FORWARD I: mirvetuximab soravtansine vs chemo in platinum-resistant ovarian cancer
Kathleen Moore • 29 Sep 2019
3:58
SOLO-1: practice changing data on olaparib for ovarian cancer
Kathleen Moore • 19 Oct 2018
2:27
The PAOLA-1 study: olaparib and bevacizumab for ovarian cancer
Kathleen Moore • 19 Oct 2018
7:39
Ovarian news from ESMO 2018: SOLO-1 results for olaparib
Kathleen Moore • 21 Oct 2018

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals